Managing seborrheic dermatitis using ketoconazole shampoo, Nizoral, and oils like MCT and coconut oil. The user considers shaving their head and consulting a dermatologist.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
Cialis is used to manage erectile dysfunction caused by finasteride and dutasteride, with mixed results. Some users report improvement, while others consider stopping the medication due to side effects.
Hair follicles often go dormant rather than die, and treatments like minoxidil can help revive them. Scalp health and stimulation, such as massages and using products like sulphur soap, are also important for hair regrowth.
Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Hair fibers can effectively cover thinning hair when used with minoxidil and hairspray but require daily application and can be inconvenient in certain conditions. Some users prefer treatments like finasteride, dutasteride, microneedling, or wigs due to the maintenance and limitations of hair fibers.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
DHT affects hair follicles, contributing to hair loss, but the exact mechanism is unclear. Treatments like finasteride and minoxidil are used to manage hair loss, though they may have side effects and varying effectiveness.
Diet and lifestyle changes can reduce hair shedding but won't regrow hair lost to genetic male pattern baldness. Treatments like finasteride and dutasteride are necessary for significant hair regrowth.
The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
Microneedling with minoxidil significantly boosts hair growth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.
The user successfully regrew hair using Finasteride, Minoxidil, and microneedling, achieving thicker hair and a fuller hairline. They recommend this method over hair transplants, highlighting the importance of patience and consistency.
Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.
Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.
Topical minoxidil may cause skin aging effects like wrinkles and dark circles, possibly due to its alcohol content, while oral finasteride is reported to make users look younger. Switching to oral minoxidil or using moisturizers might help reduce these skin issues.
Checking vitamin and hormone levels is important for addressing hair loss, as deficiencies in vitamin D, zinc, and iron can affect hair growth. Treatments like finasteride, minoxidil, and vitamin supplements are used, but addressing deficiencies is crucial for effectiveness.
Oral biotin combined with topical minoxidil may increase hair growth rate, though the study was limited to healthy subjects and did not measure hair density. Some users report personal benefits from biotin, such as faster nail growth and healthier hair, but concerns about acne and study quality were also mentioned.
The user experienced positive hair growth results using microneedling with rosemary and mint oil, without Minoxidil, Finasteride, or RU58841. They switched from a dermaroller to a microneedling pen and targeted different scalp areas weekly.
A doctor advised against using finasteride or dutasteride during pregnancy. The user continues with oral and topical minoxidil, microneedling, tretinoin, Nizoral, and pyrilutamide.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Microneedling combined with minoxidil and finasteride shows significant hair regrowth, though opinions on its effectiveness vary. Some users report substantial benefits, while others highlight the need for more research and consistency in application.
A user reported significant facial aging after using minoxidil for hair loss, despite a good skincare routine and healthy lifestyle. They plan to switch to dutasteride and possibly stop minoxidil.